Vy9V 2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs - Rituximab and trastuzumab

Tokuyama, Hirotake, Hagi, Tomomi, Mattarollo, Stephen R, Morley, Jacqueline, Wang, Qiao, Fai-So, Hang, Moriyasu, Fuminori, Nieda, Mie and Nicol, Andrew J. (2008) Vy9V 2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs - Rituximab and trastuzumab. International Journal of Cancer, 122 11: 2526-2534. doi:10.1002/ijc.23365


Author Tokuyama, Hirotake
Hagi, Tomomi
Mattarollo, Stephen R
Morley, Jacqueline
Wang, Qiao
Fai-So, Hang
Moriyasu, Fuminori
Nieda, Mie
Nicol, Andrew J.
Title Vy9V 2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs - Rituximab and trastuzumab
Journal name International Journal of Cancer   Check publisher's open access policy
ISSN 1097-0215
0020-7136
Publication date 2008-06-01
Year available 2008
Sub-type Article (original research)
DOI 10.1002/ijc.23365
Open Access Status
Volume 122
Issue 11
Start page 2526
End page 2534
Total pages 9
Place of publication New York U.S.A.
Publisher John Wiley & Sons
Language eng
Subject C1
920102 Cancer and Related Disorders
111201 Cancer Cell Biology
1112 Oncology and Carcinogenesis
Abstract V9V2 T cells exert potent cytotoxicity toward various tumor cells and adoptive transfer of V9V2 T cells is an attractive proposition for cell based immunotherapy. V9V2 T cells expanded in the presence of Zoledronate and IL-2 express CD16 (FcRIII), which raises the possibility that V9V2 T cells could be used in conjunction with tumor targeting monoclonal antibody drugs to increase antitumor cytotoxicity by antibody dependent cellular cytotoxicity (ADCC). Cytotoxic activity against CD20-positive B lineage lymphoma or chronic lymphocytic leukemia (CLL) and HER2-positive breast cancer cells was assessed in the presence of rituximab and trastuzumab, respectively. Cytotoxicity of V9V2 T cells against CD20-positive targets was higher when used in combination with rituximab. Similarly, V9V2 T cells used in combination with trastuzumab resulted in greater cytotoxicity against HER2-positive cells in comparison with either agent alone and this effect was restricted to the CD16+V9V2 T cell population. Our results show that CD16+V9V2 T cells recognize monoclonal antibody coated tumor cells via CD16 and exert ADCC similar to that observed with NK cells, even when target cells are relatively resistant to monoclonal antibodies or V9V2 T cells alone. Combination therapy involving ex vivo expanded CD16+V9V2 T cells and monoclonal antibodies may enhance the clinical outcomes for patients treated with monoclonal antibody therapy. © 2008 Wiley-Liss, Inc.
Keyword T cell
Cellular immunotherapy
CD16
ADCC
Monoclonal antibody drugs
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: 2009 Higher Education Research Data Collection
Excellence in Research Australia (ERA) - Collection
School of Medicine Publications
 
Available Versions of this Record
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 66 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 71 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Thu, 09 Apr 2009, 20:17:04 EST by Denise Wilson on behalf of Faculty Of Health Sciences